

Received:02May 2014 • Accepted:18June2014

Short C

doi:10.15412/J.JBTW.01030703

Study of the Effect of Probiotic *Saccharomyces Boulardii* on the Treatment of Irritable Bowel Syndrome

Mohsen Akhondi-Meybodi¹, Masoud Rahimian², Hasan Salmanroghani¹, MohammadKazem Amirbeigy³, Mahmoud Baghbanian⁴, SeydYaser Ghelmani^{5*}

¹Associated professor of Gastroenterology, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran

²Assistant professor of Pulmonary and Critical care medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran

³Assistant professor of Gastroenterology, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran

⁴Assistant professor, Gastroenterology, Research center of pancreaticobiliary disease, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

⁵Resident of gastroenterology, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran

*correspondence should be addressed to SeydYaserGhelman, Resident of gastroenterology, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran; Tell: +989125238156; Fax: +98; Email: yaserghelmani@ssu.ac.ir.

ABSTRACT

Irritable bowel syndrome is the most common diagnosed gastro enteric disorder incriminated for 12% of cases of referring to gastroenterologists. Various studies have shown that the intestinal micro flora of the patients affected with IBS undergoes some changes. Therefore, it seems that the recovery of intestinal flora is a useful therapeutic approach. This study investigated the effect of probiotic *Saccharomyces Boulardii* on improving the symptoms of IBS. This study was a randomized double-blind clinical trial conducted on 60 IBS patients. The patients were divided into two groups of 30 (case and control groups). The patients in the case group received Yomogi and those in the control group got placebo. Demographic information and symptoms as abdominal pain, flatulence, diarrhea, constipation, gurgling, eructation (belching and burping), urgent defecation, and release of gas from the anus (farting and fizzling) were collected before intervention and three weeks after initiation of treatment, and analyzed. 43.3% of the patients in the case group were male and 56.7% were female. In addition, 40% of the patients in the control group were male and 60% were female. A comparison of the mean scores of abdominal symptoms in the case group before and after intervention revealed that there was a statistically significant difference between before and after intervention values for pain severity ($P=0.001$), flatulence ($P=0.001$), diarrhea ($P=0.001$), gurgling ($P=0.001$), eructation ($P=0.023$), and gas release from the anus ($P=0.001$). Yet, there was no statistically significant difference before and after intervention for symptoms of constipation ($P=0.161$), and urgent defecation ($P=0.09$). The consumption of *Saccharomyces Boulardii* reduces pain severity, flatulence, diarrhea, gurgling, eructation, and gas release from the anus in patients with IBS and improves life quality.

Key words: Probiotic, *Saccharomyces Boulardii*, Irritable Bowel Syndrome

Copyright © 2014 Mohsen Akhondi-Meybodiet al. This is an open access article distributed under the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/).

1. INTRODUCTION

Irritable bowel syndrome is the most common diagnosed gastrointestinal disorder incriminated for 12% of cases of patient presentation to gastroenterologists (1). This syndrome can directly or indirectly lead to increased health care expenses, this figure being estimated to be 30 million US dollars in America (2). Its prevalence is different among different nations. In some research conducted so far, the rate of incidence of IBS is said to be 10-15% for North America

and 11.5% in Europe (3). Since there is no definite treatment for IBS, the current treatment modalities are more of a palliative and supportive nature (4,5). Irritable bowel syndrome is a functional intestinal disturbance, which manifests itself with symptoms as abdominal pain or problem, or a change in intestinal habits in the absence of any structural disorder. Risk factors include the female gender (two or three times more prevalent), acute gastrointestinal infections (e.g., campylobacter or salmonella), and psychological factors (5-7). Various

studies have demonstrated that enteric micro-flora in patients with IBS sustains some changes and the symptoms aggravate after enteric infections (8-11). Hence, it appears that the recovery of enteric micro-flora is an appropriate therapeutic approach. One strategy for returning normal flora is the use of probiotics (12). Probiotics are useful bacteria or yeasts taken to improve health status (12). They also act as moderators of the immune response and decrease the production of cytokines. There is some strong evidence in favor of the useful role of probiotics in preventing antibiotic-induced diarrhea, traveler's syndrome, and pediatric diarrhea (13, 14). A change in the normal flora of the colon is rendered as the main cause of pathogenesis in irritable bowel syndrome. That is why the use of probiotics for the correction of the normal flora of the colon has been considered as a suitable approach and more research has been recently conducted on this issue (15,16). However, the findings of these studies have been various and relatively contradictory (17). The aim of this study was to investigate the effect of the probiotic *Saccharomyces Boulardii* (Yomogi) on improving the symptoms of IBS.

2. MATERIALS AND METHODS

This was a randomized double-blind clinical trial carried out on 60 patients with IBS after receiving the approval of the Committee of Ethics at Yazd Shahid Sadoughi University of Medical Sciences and obtaining informed written consent of each patient. The patients were selected randomly using the random numbers table. The patients were divided into two groups of 30 (case group= 30, and control group = 30). The patients in the case group received Yomogi and those in the control group got placebo. Demographic information and symptoms as abdominal pain, flatulence, diarrhea, constipation, gurgling, eructation (belching and burping), urgent defecation, and farting and fizzling were collected before intervention and three weeks after initiation of treatment and analyzed. A gastroenterologist made the diagnosis of IBS. Based on clinical signs, symptoms, and examinations, and the required and ordered laboratory hematologic tests and biochemical profile (CBC, ESR, BUN, Cr, Na, K, S/E), the assumedly required assessments including colonoscopy, colon biopsy, Anti TTG, sonography, and stool culture were done. After selecting the patients and receiving the patient inclusion criteria the patients randomly entered the three-week phase of treatment (*Saccharomyces Boulardii* vs. placebo) and were assessed at the end of the third week (at the completion of treatment). Any type of previous treatment of IBS was discontinued at the time of arrival in the study. Demographic and clinical information of the

patients (age, sex, education level, medical history, pharmacologic history, and duration of affliction with IBS) were collected in a face-to-face interview with the patients. *Saccharomyces Boulardii* and placebo were taken in the form of capsules. *Saccharomyces Boulardii* capsules contained frozen yeast powder with a coating, which was dissolvable in duodenum in the neutral pH. The placebo capsules were similar to Yomogi capsules except that they did not contain any *Saccharomyces* powder and had no coating. All the capsules could be kept at room temperature. The recommended dose of *saccharomyces Boulardii* for reaching the enteric colonization (10 colonies) was one cap/pd (one capsule per day postprandial, i.e., following a meal). The patients were asked to score the severity of their digestive symptoms on a Likert scale containing four subscales of 0-4 points. These symptoms included abdominal pain, flatulence, urgent emptying of the bowel (defecation), diarrhea, constipation (or obstipation) gurgling, eructation (belching and burping), and gas release from the anus (farting and fizzling). The questionnaires were completed in the first and third weeks of intervention. The required data were accumulated from the patients via interviews recorded in checklist and analyzed with SPSS version 15. Data were analyzed by t-test and Paired samples t-tests.

3. RESULTS AND DISCUSSION

The results of the study showed that 13 (43.3%) patients under investigation in the case group were male and 17 (56.7%) were female. In addition, there were 12 (40%) male and 18 (60%) female patients in the control group. There was no statistically significant difference between the two groups in terms of gender ($P=0.793$). Furthermore, the mean age of the patients was 37.23 ± 16.712 years in the case group and 44.20 ± 13.976 years in the control group which were not significantly different using the T-test ($P=0.085$). Comparing the mean scores of abdominal symptoms before intervention, there was no significant difference between the two groups regarding pain severity ($P=0.398$), flatulence ($P=0.130$), diarrhea ($P=0.155$), constipation ($P=0.171$), gurgling ($P=0.317$), eructation ($P=0.599$), urgent defecation ($P=0.137$), and gas release from the anus ($P=0.225$). Comparing the mean scores of abdominal symptoms after intervention, the results revealed that there was a significant difference between the two groups regarding pain severity ($P=0.008$), diarrhea ($P=0.001$), and gurgling ($P=0.317$). Yet, there was no significant difference between the two groups after intervention regarding flatulence ($P=1$), constipation ($P=0.121$), eructation ($P=0.197$), urgent defecation ($P=0.630$), and gas release from the anus ($P=0.071$) (

Table 1).

Table 1. Comparison of mean scores of abdominal symptoms between the two groups after intervention

symptoms	case group		control group		F	t	p-value*
	mean	S.D	mean	S.D			
pain	1.3	0.466	1.83	0.95	23.439	-2.761	0.008
flatulence	2	0.263	2	0.455	2.320	0.000	1
diarrhea	1.7	0.466	2	0	152.25	-3.525	0.001
constipation	1.3	0.466	1	0.346	10.807	1.573	0.121
gurgling	1.3	0.466	1	0	152.25	3.525	0.001
belching and burping	1.5	0.509	1.67	0.479	3.625	-1.306	0.197
urgent defecation	1.73	0.45	1.67	0.606	5.159	0.484	0.63
farting and fizzling	1.43	0.504	1.67	0.479	2.174	-1.837	0.071

*: t-test

Comparing the mean scores of abdominal symptoms in the case group before and after intervention, the results revealed that there was a significant difference regarding pain severity ($P=0.001$), flatulence ($P=0.001$), diarrhea ($P=0.001$), gurgling ($P=0.000$), eructation ($P=0.023$), and

gas release from the anus ($P=0.001$). Yet, there was no significant difference between before and after intervention regarding constipation ($P=0.161$), and urgent defecation ($P=0.090$),

Table 2).

Table 2. Comparison of mean scores of abdominal symptoms in the case group before and after intervention

symptoms	before		after		t	p-value*
	mean	S.D	mean	S.D		
pain	3.13	0.346	1.3	0.466	15/503	0.001
flatulence	2.57	0.679	2	0.263	4/572	0.001
diarrhea	2.07	0.254	1.7	0.466	4/097	0.001
constipation	1.23	0.43	1.3	0.466	-1/439	0.161
gurgling	2.67	0.844	1.3	0.466	8/411	0.001
belching and burping	1.67	0.479	1.5	0.509	2/408	0.023
urgent defecation	1.97	0.718	1.73	0.45	1/756	0.09
farting and fizzling	2.03	0.615	1.43	0.504	4/539	0.001

*: Paired samples t-tests

Additionally, comparing the mean scores of abdominal symptoms in the control group before and after

intervention, the results revealed that there was a significant difference regarding pain severity ($P=0.001$),

flatulence ($P=0.005$), and gurgling ($P=0.001$). Yet, there was no significant difference between before and after intervention regarding diarrhea ($P=1$), constipation

($P=0.573$), eructation ($P=0.161$), urgent defecation ($P=0.662$), and gas release from the anus ($P=0.231$)

Table 3).

Table 3. Comparison of mean scores of abdominal symptoms in the control group before and after intervention

symptoms	before		after		t	p-value*
	mean	S.D	mean	S.D		
pain	3.07	0.254	1.83	0.95	7/526	0.001
flatulence	2.33	0.479	2	0.455	3/01	0.005
diarrhea	2	0	2	0	0	1
constipation	1.1	0.305	1.13	0.346	-0.571	0.573
gurgling	2.47	0.681	1	0	11/789	0.001
belching and burping	1.6	0.498	1.67	0.479	-1/439	0.161
urgent defecation	1.7	0.651	1.67	0.606	0.441	0.662
farting and fizzling	1.83	0.648	1.67	0.479	1/233	0.231

*: Paired samples t-tests

- This study investigated the effect of the probiotic *Saccharomyces Boulardii* on the treatment of irritable bowel syndrome. In our study, there was no significant difference in the mean scores of pain severity between the two groups before the intervention while there was difference in the mean scores of pain severity in the two groups after intervention ($P=0.004$). Although in the respect was a reduction in pain severity in both groups after the intervention compared to before the intervention, the pace of reduction in pain severity after intervention was more outstanding in the case group compared to the control group indicating that there was an improvement in abdominal symptoms following the consumption of *Saccharomyces Boulardii*. The results of the improvement of abdominal symptoms are consistent with the findings of Qanaee, Kim, and Edler(18-21). In our study, abdominal pain and diarrhea were the most common IBS-related abdominal symptoms. In Serra J's study, abdominal pain was the patients' most frequent complaint (22), while in the study by Lembo T conducted on 443 patients affected with IBS, the patients' most common complaint was flatulence (60%) and 29% of the patients complained of abdominal pain (22). Comparing the mean score of diarrhea severity, the results demonstrated that there was a statistically significant difference before and after intervention in the case group ($P=0.001$) while there was no statistically significant difference before and after intervention in the control group comparing the mean score of diarrhea severity ($P=1$). This indicated that the probiotic *Saccharomyces Boulardii* reduced the severity of diarrhea. This is consistent with the findings of the systematic review study by McFarland, Kotowask M, and Villarruel G (23, 24). Moreover, Szajewska H carried out a meta-analysis in 2007 aimed at studying the effect of *Saccharomyces Boulardii* on the treatment of diarrhea in children finding that the consumption of *Saccharomyces Boulardii* reduced the length of the episode of diarrhea (25). In the present study, there was a significant difference in the case group ($P=0.001$) and in the control group ($P=0.005$) regarding the

rate of flatulence before and after intervention, yet, there was no significant difference between the two groups in this regard after intervention. This means that we cannot claim that only *Saccharomyces Boulardii* affected flatulence, this being consistent with the claims made by Kim & Edler. Bozzochi and Hun claimed in their study that probiotics were effective in decreasing flatulence (26,27). Regarding constipation and urgent defecation, there was no significant difference in the case group before and after intervention. The study by Osullivan aiming at investigating the effect of the probiotic *Lactobacillus* on abdominal symptoms of IBS was conducted on 25 patients. It showed that although the symptoms of diarrhea, abdominal pain, and urgent defecation decreased after intervention compared to before the intervention, the difference was not statistically significant (28). Report on urgent defecation was consistent with our study; nevertheless, it was not coherent with our findings re-getting diarrhea and abdominal pain.

4. CONCLUSION

The findings of this research showed that the use of *Saccharomyces Boulardii* (Yomogi) can be effective in improving the symptoms of IBS, specifically pain severity, diarrhea, eructation, and gas release from the stomach. Considering the high prevalence of IBS and lack of effective treatment, the provision of a therapeutic modality, which improves the symptoms of the disease, though to a small degree, regarded as an important achievement. One of the limitations of our study was that we followed the patients just for three weeks. For future study and obtaining further accurate results, it is advocated that more subjects with larger sample volumes and longer follow-up periods be taken.

ACKNOWLEDGMENT

No mentioned acknowledgment by any authors.

AUTHORS CONTRIBUTION

This work was carried out in collaboration between all authors.

CONFLICT OF INTEREST

The authors have declared no potential conflicts of interests with respect to the authorship and/or publication of this article.

REFERENCES

1. Everhart JE, Renault PF. Irritable bowel syndrome in office-based practice in the United States. *Gastroenterology*. 1991;100(4):998-1005.
2. Sandler RS, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, et al. The burden of selected digestive diseases in the United States. *Gastroenterology*. 2002;122(5):1500-11.
3. Thompson WG, Irvine EJ, Pare P, Ferrazzi S, Rance L. Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire. *Digestive diseases and sciences*. 2002;47(1):225-35.
4. Agrawal A, Whorwell PJ. Irritable bowel syndrome: diagnosis and management. *BMJ*. 2006;332(7536):280-3.
5. Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. *Gut*. 2007;56(12):1770-98.
6. Cremonini F, Talley NJ. Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors. *Gastroenterology clinics of North America*. 2005;34(2):189-204.
7. Ruigomez A, Garcia Rodriguez LA, Panes J. Risk of irritable bowel syndrome after an episode of bacterial gastroenteritis in general practice: influence of comorbidities. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*. 2007;5(4):465-9.
8. Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. *JAMA : the journal of the American Medical Association*. 2004;292(7):852-8.
9. Malinen E, Rinttila T, Kajander K, Matto J, Kassinen A, Krogus L, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. *The American journal of gastroenterology*. 2005;100(2):373-82.
10. Quigley EM, Flourie B. Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. *Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society*. 2007;19(3):166-72.
11. Spiller RC. Role of infection in irritable bowel syndrome. *Journal of gastroenterology*. 2007;42(Suppl 17):41-7.
12. Elmer GW ML, McFarland M. Introduction. In: *The power of probiotics:*

improving your health with beneficial microbes. Binghamton, NY: Haworth Press, 2007:1-24.

13. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. *The American journal of gastroenterology*. 2006;101(4):812-22.
14. Szajewska H, Ruszczynski M, Radzikowski A. Probiotics in the prevention of antibiotic-associated diarrhea in children: a meta-analysis of randomized controlled trials. *The Journal of pediatrics*. 2006;149(3):367-72.
15. Kim HJ, Camilleri M, McKinzie S, Lempke MB, Burton DD, Thomforde GM, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. *Alimentary pharmacology & therapeutics*. 2003;17(7):895-904.
16. Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. *The American journal of gastroenterology*. 2000;95(5):1231-8.
17. Sen S, Mullan MM, Parker TJ, Woolner JT, Tarry SA, Hunter JO. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. *Digestive diseases and sciences*. 2002;47(11):2615-20.
18. Adler SN. The probiotic agent Escherichia coli M-17 has a healing effect in patients with IBS with proximal inflammation of the small bowel. *Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver*. 2006;38(9):713.
19. Kim YG, Moon JT, Lee KM, Chon NR, Park H. [The effects of probiotics on symptoms of irritable bowel syndrome]. *The Korean journal of gastroenterology = TaehanSohwagiHakhoe chi*. 2006;47(6):413-9.
20. Mansour-Ghanaei F, Dehbashi N, Yazdanparast K, Shafaghi A. Efficacy of saccharomyces boulardii with antibiotics in acute amoebiasis. *World journal of gastroenterology : WJG*. 2003;9(8):1832-3.
21. Serra J, Azpiroz F, Malagelada JR. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. *Gut*. 2001;48(1):14-9.
22. Lembo T, Naliboff B, Munakata J, Fullerton S, Saba L, Tung S, et al. Symptoms and visceral perception in patients with pain-predominant irritable bowel syndrome. *The American journal of gastroenterology*. 1999;94(5):1320-6.
23. Kotowska M AP, Szajewska H. accharomycesboulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. *Alimentary pharmacology & therapeutics*. 2005;21(5):583-90.
24. Villarruel G, Rubio DM, Lopez F, Cintioni J, Gurevich R, Romero G, et al. Saccharomyces boulardii in acute childhood diarrhoea: a randomized, placebo-controlled study. *Acta Paediatr*. 2007;96(4):538-41.
25. Szajewska H, Skorka A, Dylag M. Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children. *Alimentary pharmacology & therapeutics*. 2007;25(3):257-64.
26. Bazzocchi G, Gionchetti P, Almerigi PF, Amadini C, Campieri M. Intestinal microflora and oral bacteriotherapy in irritable bowel syndrome. *Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver*. 2002;34(Suppl 2):S48-53.
27. Hun L. Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. *Postgraduate medicine*. 2009;121(2):119-24.
28. O'Sullivan MA, O'Morain CA. Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. *Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver*. 2000;32(4):294-301.